Longevity: Einblicke in eine exklusive Welt: Wo Superreiche das ewige Leben suchen

Gstaad, a Swiss Alpine town, hosts the world's most exclusive conference on Longevity-Investors. 120 people gather with the belief that death is negotiable, united in the pursuit of making money from longevity. To attend the 5,000 Euro event, participants must prove they've invested at least 30 million Euros. I attended the conference to understand the scene and hear what the smartest minds in longevity research discuss with the world's richest investors behind closed doors.

A 5,000 Euro ticket to the conference, which calls itself "the world's most exclusive conference for Longevity-Investors," costs. Private individuals often bring a bank statement showing their multi- or billion-dollar fortune, says Tobias Reichmuth, who runs the event with Marc Bernegger of Longevity-Investment firm Maximon.

At the luxurious Le Grand Bellevue, participants discuss GLP-1 drugs for weight reduction, health prevention, and startups researching rejuvenation and disease reversal. The hotel looks like a glamorous resort resort, but inside, it's a world of exclusivity. The atmosphere is fancy, but still casual, unlike other medical conferences.

Medical professionals mingle with wealthy investors, and the conversation ranges from biotech investments to health prevention. One doctor at the conference, Emil Kendziorra, runs a business freezing human bodies after death through a controversial process called kryokonservierung. Despite past connections to Jeffrey Epstein, he asserts that the billion-dollar potential of longevity far outweighs any past indiscretions.

Longevity is projected to become a multi-billion-dollar industry, with the global market set to double to $62 billion by 2034, according to Emergen Research. The market encompasses biotech, preventive medicine, advanced diagnostics, age-specific technologies, and specialized financial products. All these investments aim to help people not just live longer, but healthier lives.

By 2050, the number of people over 60 worldwide is expected to reach 2.1 billion. In 2025, venture capital poured $1.2 billion into longevity research, with the US contributing $1.1 billion. Prominent investors include GV, Alphabet's venture capital arm, Arch Venture Partners, Casdin Capital, and Khosla Ventures. The investment volume is growing rapidly, with $3.7 billion flowing into longevity biotechnology in the first quarter of 2023, a 56 percent increase from the previous year.

As artificial intelligence faces market challenges, investors are focusing on the health sector, with one organizer predicting a 1,000 percent potential return.